Series A+ · Biotech
Degron Therapeutics: Series A+
Develops molecular glue degrader medicines targeting previously undruggable proteins
Funding history
Series A+ · This round$40M
Loading rounds…
Develops molecular glue degrader medicines targeting previously undruggable proteins